Molecular Diagnostics

分子病理学核心的作用是通过提供专门的分子生物学分析，为有效评估疾病状态、患者和动物模型对治疗的反应的分子基础，以及移植干预后的免疫重建分析，为格兰特计划的研究人员提供支持。此核心提供的服务是可扩展的服务 超越常规的临床前研究和标准的临床护理。该核心为监测治疗结果、检测早期疾病复发和最小疾病状态的项目提供分子测试。 对实验疗法的快速和定量评估对于加速和准确分析潜在疗效是必要的。最小残留疾病的定量评估将使用TaqMan化学进行，以对疾病反应和临床上潜在的复发进行强有力的评估 标本。除了标准的实时聚合酶链式反应方法外，核心将利用新的大规模并行的下一代测序技术来改进对最小残留疾病的检测，并提供对免疫重建的评估。这个核心集中执行分子程序将避免程序中的重复工作，并确保及时、高效和一致的高质量 结果。

The role of the Molecular Pathology Core is to support investigators in the Program Project Grant by providing dedicated molecular biological analyses for effective assessment of disease states, the molecular basis of response to therapy both in patients and in animal models, and the analysis of immune reconstitution following transplant interventions. The services provided by this Core are those that extend beyond routine preclinical studies and standard clinical care. This Core provides molecular testing for projects that monitor treatment outcomes, detect eariy disease recurrence and minimal disease states. Rapid and quantitative assessment of experimental therapies is necessary for accelerated and accurate analyses of potential efficacy. Quantitative assessment of minimal residual disease will be performed using TaqMan chemistry for a robust assessment of disease response and potential recurrence on clinical specimens. The core will utilize novel, massively parallel next generation sequencing technology in addition to the standard real-time PCR methods to improve detection of minimal residual disease and provide an assessment of immune reconstitution. The centralized performance of the molecular procedures by this Core will avoid duplication of efforts in the program and ensure timely, efficient and consistently high quality results.